Cargando…

Assessing the Effects of Modern Renoprotective Agents in Preventing Progression of Renal Composite Outcomes in Patients with Type 2 Diabetes: A Network Meta-analysis

BACKGROUND AND AIMS: Type 2 diabetes is one of the leading causes of the development and progression of diabetic kidney disease, culminating in end-stage renal disease. Approximately two decades after successful implementation of the renin–angiotensin–aldosterone blocking system, three classes of ag...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ghosal, Samit, Sinha, Binayak
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9943809/ https://www.ncbi.nlm.nih.gov/pubmed/36566447 http://dx.doi.org/10.1007/s13300-022-01359-0

Ejemplares similares

Finerenone in type 2 diabetes and renal outcomes: A random-effects model meta-analysis
por: Ghosal, Samit, et al.
Publicado: (2023)

Exploring the comparative cardiovascular death benefits of sodium–glucose cotransporter 2 inhibitors in type 2 diabetes: a frequentist and Bayesian network meta-analysis-based scoring
por: Ghosal, Samit, et al.
Publicado: (2023)

Assessing the need for pioglitazone in the treatment of patients with type 2 diabetes: a meta-analysis of its risks and benefits from prospective trials
por: Sinha, Binayak, et al.
Publicado: (2020)

Meta‐analysis of the effects of sodium glucose cotransporter 2 inhibitors in non‐alcoholic fatty liver disease patients with type 2 diabetes
por: Sinha, Binayak, et al.
Publicado: (2020)

A Target HbA1c Between 7 and 7.7% Reduces Microvascular and Macrovascular Events in T2D Regardless of Duration of Diabetes: a Meta-Analysis of Randomized Controlled Trials
por: Sinha, Binayak, et al.
Publicado: (2021)

A meta-analysis of the effects of glucagon-like-peptide 1 receptor agonist (GLP1-RA) in nonalcoholic fatty liver disease (NAFLD) with type 2 diabetes (T2D)
por: Ghosal, Samit, et al.
Publicado: (2021)

A Meta-Analysis of the Effect of Sodium Glucose Cotransporter-2 Inhibitors on Metabolic Parameters in Patients With Polycystic Ovary Syndrome
por: Sinha, Binayak, et al.
Publicado: (2022)

Sodium-Glucose Cotransporter-2 Inhibitors (SGLT-2i) Reduce Hospitalization for Heart Failure Only and Have No Effect on Atherosclerotic Cardiovascular Events: A Meta-Analysis
por: Sinha, Binayak, et al.
Publicado: (2019)

LBODP046 Reduction In "Cardiovascular Death Or Hospitalisation For Heart Failure" With Sglt-2is Is Dependent On Weight Reduction: A Meta-regression Analysis
por: Ghosal, Samit, et al.
Publicado: (2022)

Quantitative measure of asymptomatic cardiovascular disease risk in Type 2 diabetes: Evidence from Indian outpatient setting
por: Ghosal, Samit, et al.
Publicado: (2020)

Gliptins and Cardiovascular Outcomes: A Comparative and Critical Analysis after TECOS
por: Ghosal, Samit, et al.
Publicado: (2016)

Rapid sputum testing and not thermal screening alone should be the first-line screening test at airports: A Bayesian analysis
por: Ghosal, Samit, et al.
Publicado: (2020)

Estimation of effects of nationwide lockdown for containing coronavirus infection on worsening of glycosylated haemoglobin and increase in diabetes-related complications: A simulation model using multivariate regression analysis
por: Ghosal, Samit, et al.
Publicado: (2020)

Heterogeneity in cardiovascular death or hospitalization for heart failure benefits with flozins is linked to weight
por: Ghosal, Samit, et al.
Publicado: (2023)

Increase in the risk of type 2 diabetes during lockdown for the COVID19 pandemic in India: A cohort analysis
por: Ghosal, Samit, et al.
Publicado: (2020)

Is insulin degludec a more effective treatment for patients using high doses of insulin glargine but not attaining euglycemia? Some case reports from India
por: Sinha, Binayak, et al.
Publicado: (2014)

“Compliance of the Indian National Task Force guidelines for COVID-19 recommendation by Indian doctors – A survey"
por: Gangopadhyay, Kalyan Kumar, et al.
Publicado: (2020)

Linear Regression Analysis to predict the number of deaths in India due to SARS-CoV-2 at 6 weeks from day 0 (100 cases - March 14th 2020)
por: Ghosal, Samit, et al.
Publicado: (2020)

The Renal Composite Benefit of Sodium Glucose Co-Transporter 2 Inhibitors Should Ideally Be Assessed Based on a Standardised Definition: A Meta-Analysis of Randomised Controlled Trials
por: Ghosal, Samit, et al.
Publicado: (2023)

Selecting antihyperglycemic agents with proven safety: A must in COVID-19 era
por: Ghosal, Samit
Publicado: (2020)

Renoprotection and the Bardoxolone Methyl Story – Is This the Right Way Forward? A Novel View of Renoprotection in CKD Trials: A New Classification Scheme for Renoprotective Agents
por: Onuigbo, Macaulay
Publicado: (2013)

Potential Renoprotective Agents through Inhibiting CTGF/CCN2 in Diabetic Nephropathy
por: Wang, Songyan, et al.
Publicado: (2015)

Renoprotective effects of atorvastatin compared with pravastatin on progression of early diabetic nephropathy
por: Takazakura, Akiko, et al.
Publicado: (2015)

Renoprotective Effect of Intraoperative Dexmedetomidine in Renal Transplantation
por: Liu, Zhenzhen, et al.
Publicado: (2022)

Antioxidants as Renoprotective Agents for Ischemia during Partial Nephrectomy
por: Buys-Gonçalves, Gabriela F., et al.
Publicado: (2019)

Exploring the mechanisms of renoprotection against progressive glomerulosclerosis
por: OITE, Takashi
Publicado: (2011)

Retracted: Renoprotective Effect of Intraoperative Dexmedetomidine in Renal Transplantation
por: Methods in Medicine, Computational and Mathematical
Publicado: (2023)

Renoprotection with SGLT2 inhibitors in type 2 diabetes over a spectrum of cardiovascular and renal risk
por: Giorgino, Francesco, et al.
Publicado: (2020)

Drugs that slow the progression of diabetic kidney disease: are renoprotective effects attenuated in heart failure?
por: Packer, Milton, et al.
Publicado: (2023)

Renoprotective effects of a dipeptidyl peptidase 4 inhibitor in a mouse model of progressive renal fibrosis
por: Uchida, Takahiro, et al.
Publicado: (2017)

Renoprotective effects of telmisartan after unilateral renal ablation in rats
por: Matsuo, Tomohiro, et al.
Publicado: (2013)

Molecular Mechanisms of Curcumin Renoprotection in Experimental Acute Renal Injury
por: Fan, Youling, et al.
Publicado: (2017)

FRI651 Usage Of Modern Sulphonylureas And Metformin Fixed Dose Combination (fdc) In Type 2 Diabetes Mellitus (t2dm) Patients With Established Complications
por: M, Aushili, et al.
Publicado: (2023)

Beat it early: putative renoprotective haemodynamic effects of oral hypoglycaemic agents
por: Gnudi, Luigi, et al.
Publicado: (2016)

Renoprotective Effect of Ocimum Basilicum (Basil) Against Diabetes-induced Renal Affection in Albino Rats
por: Almalki, Daklallah Ahmed
Publicado: (2019)

Reply to letter to the editor regarding article: Estimation of effects of nationwide lockdown for containing coronavirus infection on worsening of glycosylated haemoglobin and increase in diabetes-related complications: A simulation model using multivariate regression analysis (Ghosal et al.)
por: Ghosal, Samit
Publicado: (2020)

Importance of achieving the composite endpoints in diabetes
por: Unnikrishnan, Ambika Gopalakrishnan, et al.
Publicado: (2013)

Renoprotective effects of garlic
por: Nasri, Hamid
Publicado: (2013)

Renoprotective effects of metformin
por: Nasri, Running Hamid
Publicado: (2013)

The renoprotective effects of sulodexide
por: Olde Engberink, Rik HG, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_v6s3hu6jpddnb3m4u88kn0ut5n